Market Research Logo

Organ Transplant Immunosuppressive Markets

Improved surgical techniques and organ preservation, understanding of immunologic barriers, and the development of newer and more potent immunosuppressives have combined to improve survival of transplant patients and grafts. Rejection remains the major barrier to long-term graft survival in patients, organ transplantation therapy is highly dependent on the success of immunosuppressants to suppress the recipient’s immune responses to the foreign organ.

Most transplant patients require lifelong immunosuppressive therapy to prevent rejection, except when human leukocyte antigen (HLA)-identical transplants are used. The number of organ transplants performed worldwide is approximately 70,000 annually. As medical science extends the life expectancy of patients with transplanted organs, demand continues to increase for safe, effective immunosuppressants to control transplant rejection.

Kalorama Information's Organ Transplant Immunosuppressive Markets is focused on immunosuppressants utilized in solid organ transplantation. It provides an in depth look into the trends that have shaped today’s use of transplant immunosuppression regimens, and details the current and future global market. Included in this report:

  • Detailed statistics on Transplant Need, Organ Transplant Procedures, Costs, Patient Waiting Lists, and Patient Survival Rates
  • Immunosupressive Current Market and Forecasts
  • Breakouts of Immunosuppressive Drugs by Drug Type and by Organ Transplanted
  • Regional Breakout of Immunosuppressive Sales (US, Europe, Asia/Pacific, Rest of World)
  • Market Share of Immunosuppressive Market
  • Review of Current Products and New Products in Development
  • Profiles of Immunosuppressive Market Competitors

As part of Kalorama Information's information-gathering process, this report consists of primary research. An exhaustive search of medical and corporate literature was conducted. But interviews with executives in the market were used to build models and test assumptions in this report.

Pharmaceutical marketing directors, executives in the organ transplant market, as well as investors looking at this market are among those who will find this report a useful resource.


  • Executive Summary
    • OVERVIEW
    • SCOPE AND METHODOLOGY
    • SOLID ORGAN TRANSPLANTATION
      • Long-Term Survival
    • SHORTAGE OF DONOR ORGANS
    • COST OF TRANSPLANTATION
    • ORGAN TRANSPLANTATION TRENDS IN THE U.S.
      • Organ Waiting List
        • Table Waiting List Candidates (Active and Inactive Combined), in U.S., 2004-2005
        • Table Current Organ Waiting List, Number of Transplant Procedures and Number of Donor Organs Recovered, in U.S., 2007
        • Table Growth in Number of Transplanted and Recovered Organs, in U.S., 2004-2005
        • Table Unadjusted One-and Five-Year Patient Survival by Organ, in U.S.
    • ORGAN TRANSPLANT TRENDS IN EUROPE
      • Table Number of Deceased Donor's Organs Used for Transplant, by Organ, as Reported by Eurotransplant, from 2002-2006
      • Table Current Waiting List for Solid Organs, as Reported by Eight European Countries, as of September 2007
    • IMMUNOSUPPRESSION IN TRANSPLANTATION
    • IMMUNOSUPPRESSION THERAPY
      • Table Chronological Development of Transplant Immunosuppressive Therapies
    • TRENDS IN USE OF IMMUNOSUPPRESSANTS
      • Trend from Calcineurin Inhibitors to Tacrolimus
      • Trend From Use of Azathioprine to Mycophenolate Mofetil
    • IMMUNOSUPPRESSANT MARKET ANALYSIS
      • Table Global Transplant Immunosuppressant Market, 2002-2012
      • Immunosuppressive Market by Drug Classification
        • Table Market Share of Immunosuppressive Categories, 2006
    • IMMUNOSUPPRESSANT SALES BY GEOGRAPHICAL REGION
      • Table Immunosuppressant Sales by Geographical Region, 2006
      • Table Immunosuppressant Market, by Transplanted Organ, 2006 (US millions)
  • Solid Organ Transplantation
    • INTRODUCTION
    • HISTORY OF ORGAN TRANSPLANTATION
      • Table Landmarks in Organ Transplantation in the United States and Canada
    • PROGRESS AND LIMITATIONS IN SOLID ORGAN REPLACEMENT
    • LONG-TERM SURVIVAL
    • SHORTAGE OF DONOR ORGANS
    • COST OF TRANSPLANTATION
      • Table Estimated US Average First-Year Billed Charges per Transplant, 2005
    • EVOLUTION OF ORGAN DONATION AND PROCUREMENT
    • NATIONAL TRANSPLANT ACT
    • ORGAN TRANSPLANT TRENDS IN THE U.S.
      • Organ Waiting List
        • Table Waiting List Candidates (Active and Inactive Combined), in U.S., 2004-2005
        • Table Current Organ Waiting List, Number of Transplant Procedures Performed and Number of Donor Organs Recovered, in U.S., 2007
        • Table Growth in Number of Transplanted and Recovered Organs, in U.S., 2004-2005
        • Table Unadjusted One-and Five-Year Patient Survival by Organ, in U.S.
        • Table Unadjusted One-and Five-Year Graft Survival by Organ, in U.S.
    • ORGAN TRANSPLANT TRENDS IN EUROPE
    • NUMBER OF ORGANS TRANSPLANTED IN EUROPE
      • Table Number of Deceased Donor's Organs Used for Transplant, by Organ, as Reported by Eurotransplant, from 2002-2006
      • Table Number of Deceased Donor's Organs Used for Transplant, by Organ and Country, as Reported by Eurotransplant, 2002-2006
      • Table Summary of Donor and Transplant Activity in the United Kingdom and the Republic of Ireland for 2005-2006
      • Table Current Waiting List for Solid Organs, as Reported by Eight European Countries, as of September 2007
    • ORGAN TRANSPLANTATION PROCEDURES
    • HEART TRANSPLANTATION
      • History of Heart Transplantation
      • Indications/Contraindications for Heart Transplant
      • Status of Heart Transplantation
    • INTESTINE TRANSPLANTATION
      • History of Intestine Transplantation
      • Indications for Intestine Transplantation
      • Status of Intestine Transplantation
    • KIDNEY TRANSPLANTATION
      • History of Kidney Transplantation
      • Indications/Contraindications for Kidney Transplantation
      • Status of Kidney Transplantation
    • LIVER TRANSPLANTATION
      • History of Liver Transplantation
      • Indications/Contraindications of Liver Transplantation
      • Status of Liver Transplantation
    • LUNG TRANSPLANTATION
      • History of Lung Transplantation
      • Indications/Contraindications of Lung Transplantation
      • Status of Lung Transplantation
    • PANCREAS TRANSPLANTATION
      • Pancreatic Islet Cell Transplantation
      • History of Pancreas Transplantation
      • Indications/Contraindications Pancreas Transplantation
      • Status of Pancreas Transplantation
    • THE IMMUNE SYSTEM AND ORGAN TRANSPLANTATION
    • POSTTRANSPLANTATION COMPLICATIONS
      • Organ Rejection
      • Hyperacute Rejection
      • Accelerated Rejection
        • Table Types of Transplant Rejection, by Organ
      • Acute Rejection
      • Chronic Rejection
    • INFECTION
    • RENAL DISORDERS
    • CANCER
    • OTHER COMPLICATIONS
    • FUTURE DIRECTIONS IN ORGAN TRANSPLANTATION
      • Stem Cells and Tissue Engineering
      • Xenotransplantation
  • Transplant Immunosuppressive Therapies
    • INTRODUCTION
    • THE IMMUNE SYSTEM
      • Functions of the Immune System
    • IMMUNOSUPPRESSION
      • Immunosuppression Therapy
      • Tolerance Induction
    • HISTORY OF THE DEVELOPMENT OF TRANSPLANT IMMUNOSUPPRESSIVE
      • Table Chronological Development of Transplant Immunosuppressive Therapies
    • DESCRIPTION OF IMMUNOSUPPRESSANT AGENTS
      • Table Most Commonly Prescribed Transplant Immunosuppressant Agents
      • Corticosteroids
      • Calcineurine Inhibitor Agents
      • Cyclosporine
      • Tacrolimus
      • mTOR inhibitors
      • Antiproliferative Agents
    • MONOCLONAL ANTIBODIES
      • Muromonab-CD3
      • Basiliximab
      • Daclizumab
    • POLYCLONAL ANTIBODIES
      • Antithymocyte globulin-equine and Antithymocyte globulin-rabbit
    • IMMUNOSUPPRESSANT REGIMENS
      • Designing Immunosuppression Regimens
      • Induction Therapy
    • MAINTENANCE THERAPY
    • ORGAN REJECTION THERAPY
      • Hyperacute Rejection
      • Accelerated Acute Rejection
      • Acute Rejection
      • Chronic Rejection
    • TRENDS IN IMMUNOSUPPRESSIVE REGIMENS
      • Steroid Avoidance/Eliminating Regimens on Increase
        • Table Steroid Avoidance Rate at Discharge, 1996 to 2005 Recipients of Deceased Donor Kidneys
        • Table Steroid Avoidance Rate at Discharge, 1996-2005 Recipients of Deceased Donor Livers
        • Table Steroid Avoidance Rate at Discharge, 1996 to 2005 Recipients of Heart Transplants
      • Minimizing Calcineurin inhibitor Regimens in Kidney Transplants
      • Downside of Transplant Immunusuppressants
      • Adverse Side Effects
        • Table Adverse Side Effects of Transplant Immunosuppressants
    • COST OF TRANSPLANT MEDICATIONS
      • Table Estimated Monthly Cost of Immunuosuppressant Drugs
    • IMMUNOSUPPRESSANT THERAPIES IN RESEARCH AND DEVELOPMENT
      • Current Research and Development
      • Circumventing the HAMA Reaction
      • Selective blocker of T-cell Activation
      • Selective Inhibitor of Janus Kinase 3
      • Inhaled Formulation of Cyclosporine
        • Table Transplant Immunosuppressant Therapies in Research and Development
    • UTILIZING GENE EXPRESSION PROFILES TO MEASURE THE EFFICACY OF IMMUNOSUPPRESSION
  • Market Analysis
    • INTRODUCTION
    • DEVELOPMENT AND EXPANSION IMMUNOSUPPRESSANTS IN ORGAN TRANSPLANTS
      • Trend from Calcineurin Inhibitors to Tacrolimus
      • Trend From Use of Azathioprine to Mycophenolate Mofetil
    • TRENDS IN THE USE OF IMMUNOSUPPRESSIVES IN SPECIFIC ORGANS
      • Trends in Kidney Transplantation
        • Table Immunosuppression Agents Used for Induction in Kidney Transplantation, 1996-2005
      • Maintenance Immunosuppression
        • Table Immunosuppression Use for Kidney Transplant Maintenance Prior to Discharge, 1996 to 2005
      • Immunosuppression Therapy for Acute Rejection
        • Table Decrease in Acute Rejection Incidence within a year of Kidney Transplant, 1996-2003
    • TRENDS IN PANCREAS TRANSPLANTATION
      • Maintenance Immunosuppression
        • Table Immunosuppression Use for PTA Maintenance Prior to Discharge, 1996 to 2005
    • TRENDS IN LIVER TRANSPLANTATION
      • Liver Maintenance Immunosuppression
      • Immunosuppression Therapy for Rejection
        • Table Immunuosuppression Use: Liver Antirejection Treatment from Transplant to One Year Posttransplant, 1994-2003
    • TRENDS IN INTESTINE TRANSPLANTATION
      • Intestine Maintenance Immunosuppression
        • Table Immunosupression Use for Maintenance Prior to Discharge for Intestine Transplants, 1995-2004
      • Antirejection Treatment for Intestine Transplantation
    • TRENDS IN LUNG TRANSPLANTATION
      • Table Immunosuppression Use for Induction in Lung Transplantation, 1996-2005
      • Lung Maintenance Immunosuppression
        • Table Immunosuppression Use of Maintenance Prior to Discharge for Lung Transplant Recipients, 1996-2005
      • Immunosuppression to Treat Acute Lung Rejection
        • Table Immunosuppression Use for Antirejection of Lung Transplant up to One Year Following Transplantation, 1995-2004
    • TRENDS IN HEART TRANSPLANTATION
      • Table Immunosuppression Use for Induction for Recipients of Heart Transplants, 1996-2005
      • Immunosuppressant Usage One Year After Transplant
        • Table Immunosuppression Usage Rates from Discharge to One Year Post-Transplantation for Heart Recipients, 1994 & 1995
    • TRENDS IN HEART-LUNG TRANSPLANTATION
      • Table Immunusuppression use for Induction in Heart-Lung Transplantations, 1996-2005
    • TRANSPLANT IMMUNOSUPPRESSANT MARKET
      • Introduction
        • Table Most Commonly Used Immunosuppressants, by Organ
    • MARKET AND FORECAST
      • Table Global Transplant Immunosuppressant Market, 2002-2012
    • IMMUNOSUPPRESSIVE MARKET BY DRUG CLASSIFICATION
      • Table Market Share of Immunosuppressive Categories, 2006
    • IMMUNOSUPPRESSANT SALES BY GEOGRAPHICAL REGION
      • Table Immunosuppressant Sales by Geographical Region, 2006
      • Table Value of Immunosuppressant Market, by Transplanted Organ, 2006 (US millions)
      • Table Immunosuppressant Market, by Transplanted Organ, by Percent (US millions)
    • TOP-SELLING IMMUNOSUPPRESSANT BRANDS
      • Table Top-Selling Transplant Immunosuppressants, by Brand Name, 2006
    • TRANSPLANT IMMUNOSUPPRESSANT MARKET SHARE
      • Table Transplant Immunosuppressant Market Share, by Manufacturer, 2006 ($billions)
    • STRATEGIES TO GAIN MARKET SHARE OR MARKET ENTRANCE
      • Table STRATEGIES TO GAIN MARKET SHARE OR MARKET ENTRANCE
    • GENZYME CORPORATION BUYS INTO THE TRANSPLANT IMMUNOSUPPRESSANT MARKET
    • PHARMACEUTICAL LIFECYCLE MANAGEMENT TO MAINTAIN OR GAIN MARKET SHARE
  • Company Profiles
    • ASTELLAS PHARMAUS, INC.
      • History and Lines of Business
      • Immunosuppressive Products
      • Financial Information
    • GENZYME CORPORATION
      • History and Lines of Business
    • IMMUNOSUPPRESSIVE PRODUCTS
      • Thymoglobulin
      • Lymphoglobuline
    • FINANCIAL INFORMATION
    • NOVARTIS AG
      • History and Lines of Business
      • Immunosuppressive Products
      • Financial Information
    • F. HOFFMANN-LAROCHE LTD
      • History and Lines of Business
      • Immunosuppressant Products
      • Financial Information
    • WYETH PHARMACEUTICALS
      • History and Lines of Business
      • Immunosuppressive Product
      • Financial Information
  • Professional Organizations
  • Company Names and Addresses

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report